Literature DB >> 20824005

Perspectives on Breast Cancer Management: Tailoring Treatment to the Individual Patient.

Christoph Thomssen1.   

Abstract

Entities:  

Year:  2008        PMID： 20824005      PMCID： PMC2930993          DOI： 10.1159/000119749

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  14 in total

1.  Outcome signature genes in breast cancer: is there a unique set?

Authors:  Liat Ein-Dor; Itai Kela; Gad Getz; David Givol; Eytan Domany
Journal:  Bioinformatics       Date:  2004-08-12       Impact factor: 6.937

2.  Urokinase-type plasminogen activator antigen and early relapse in breast cancer.

Authors:  F Jänicke; M Schmitt; K Ulm; W Gössner; H Graeff
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

3.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.

Authors:  Yixin Wang; Jan G M Klijn; Yi Zhang; Anieta M Sieuwerts; Maxime P Look; Fei Yang; Dmitri Talantov; Mieke Timmermans; Marion E Meijer-van Gelder; Jack Yu; Tim Jatkoe; Els M J J Berns; David Atkins; John A Foekens
Journal:  Lancet       Date:  2005 Feb 19-25       Impact factor: 79.321

4.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

6.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

7.  Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Authors:  Vered Stearns; Michael D Johnson; James M Rae; Alan Morocho; Antonella Novielli; Pankaj Bhargava; Daniel F Hayes; Zeruesenay Desta; David A Flockhart
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

Review 8.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

9.  Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1998-09-19       Impact factor: 79.321

10.  Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?

Authors:  B Linderholm; B Tavelin; K Grankvist; R Henriksson
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640
View more
  1 in total

1.  Multimarker Analysis of Circulating Tumor Cells in Peripheral Blood of Metastatic Breast Cancer Patients: A Step Forward in Personalized Medicine.

Authors:  Andreia de Albuquerque; Sepp Kaul; Georg Breier; Petra Krabisch; Nikos Fersis
Journal:  Breast Care (Basel)       Date:  2012-02-21       Impact factor: 2.860
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.